OCX - Oncocyte Corp
2.89
-0.030 -1.038%
Share volume: 141,220
Last Updated: 05-06-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$2.92
-0.03
-0.01%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-15-2023 | 08-10-2023 | 11-09-2023 | 04-16-2024 | 05-15-2024 | 08-08-2024 | 11-12-2024 | 03-24-2025 | |
| Total revenue | 297.000 K | 463.000 K | 429.000 K | 314.000 K | 176.000 K | 104.000 K | 115.000 K | 1.486 M | |
| Cost of revenue | 287.000 K | 191.000 K | 181.000 K | 431.000 K | 274.000 K | 54.000 K | 65.000 K | 770.000 K | |
| Gross profit | 10.000 K | 272.000 K | 248.000 K | -117.000 K | -98.000 K | 50.000 K | 50.000 K | 738.000 K | |
| 2,620.00% | -8.82% | -147.18% | 16.24% | 151.02% | 0.00% | 1,376.00% | |||
| Operating expenses | 6.234 M | 6.771 M | 5.385 M | 4.881 M | 5.688 M | 4.860 M | 5.382 M | 4.959 M | |
| Selling general and admin | 4.107 M | 4.336 M | 3.200 M | 2.334 M | 3.519 M | 2.407 M | 2.565 M | 2.559 M | |
| Research and development | 2.127 M | 2.435 M | 2.185 M | 2.547 M | 2.169 M | 2.453 M | 2.817 M | 2.400 M | |
| Total expenses | 6.521 M | 6.962 M | 5.566 M | 5.312 M | 5.962 M | 4.682 M | 13.565 M | 34.365 M | |
| 6.76% | -20.05% | -4.56% | 12.24% | -21.47% | 189.73% | 153.34% | |||
| Operating income | -6.224 M | -6.499 M | -5.137 M | -4.998 M | -5.786 M | -4.632 M | -13.515 M | -33.627 M | |
| Ebit | -6.224 M | -6.499 M | -5.137 M | -4.998 M | -5.786 M | -4.522 M | -13.462 M | -33.481 M | |
| Pretax income | 5.959 M | -8.333 M | -6.489 M | -15.992 M | -9.129 M | -4.530 M | -13.493 M | -33.511 M | |
| -239.84% | -22.13% | 146.45% | -42.92% | -50.38% | 197.86% | 148.36% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 3.033 M | -8.644 M | -6.687 M | -16.425 M | -9.129 M | 0.000 | 0.000 | 0.000 | |
| -385.00% | 22.64% | -145.63% | 44.42% | 100.00% | |||||
| Net income | 3.033 M | -8.644 M | -6.687 M | -16.425 M | -9.129 M | -4.530 M | -13.493 M | -33.511 M | |
| -385.00% | 22.64% | -145.63% | 44.42% | 50.38% | -197.86% | -148.36% |
